Drug Repurposing for Targeting Acute Leukemia With KMT2A ( MLL )-Gene Rearrangements

The treatment failure rates of acute leukemia with rearrangements of the Mixed Lineage Leukemia (MLL) gene highlight the need for novel therapeutic approaches. Taking into consideration the limitations of the current therapies and the advantages of novel strategies for drug discovery, drug repurposi...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2021-09, Vol.12, p.741413-741413
Main Authors: Tsakaneli, Alexia, Williams, Owen
Format: Article
Language:English
Subjects:
ALL
AML
drug repurposing
leukemia
MLL-rearrangements
Pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment failure rates of acute leukemia with rearrangements of the Mixed Lineage Leukemia (MLL) gene highlight the need for novel therapeutic approaches. Taking into consideration the limitations of the current therapies and the advantages of novel strategies for drug discovery, drug repurposing offers valuable opportunities to identify treatments and develop therapeutic approaches quickly and effectively for acute leukemia with -rearrangements. These approaches are complimentary to de novo drug discovery and have taken advantage of increased knowledge of the mechanistic basis of MLL-fusion protein complex function as well as refined drug repurposing screens. Despite the vast number of different leukemia associated -rearrangements, the existence of common core oncogenic pathways holds the promise that many such therapies will be broadly applicable to -rearranged leukemia as a whole.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2021.741413